Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Select your state to see jurisdictional framework, reporting obligations, and authority links. Substance information above is the same in every state.
A plain-language summary of the cited sources below. Informational only — not medical advice.
Fluoxetine works by slowing the removal of serotonin—a chemical messenger in the brain—from the spaces between nerve cells. This action is thought to improve mood and reduce obsessive thoughts or compulsive behaviours. It is approved in Australia for major depression, obsessive compulsive disorder, and premenstrual dysphoric disorder.
Fluoxetine and its active breakdown product, norfluoxetine, leave the body slowly. After a single dose, fluoxetine may take one to three days to clear; with ongoing use, this extends to four to six days. Norfluoxetine takes longer still—four to sixteen days—which means both substances build up in the body over weeks of regular dosing. This slow clearance is why stopping fluoxetine doesn't result in an immediate drop in drug levels, and why effects or side effects may persist for some time after the last dose.
Several liver enzymes break fluoxetine down into norfluoxetine, so the medication can interact with other drugs that rely on the same enzymes for processing. Fluoxetine must not be used alongside monoamine oxidase inhibitors, pimozide, or metoprolol when metoprolol is being used to treat heart failure. Anyone with a known hypersensitivity to fluoxetine or any ingredient in the formulation should not take it.
Common side effects include tiredness, diarrhoea, nausea, anxiety, dizziness, headache, trouble sleeping, nervousness, drowsiness, tremor, reduced appetite, indigestion, stomach upset, dry mouth, vomiting, itching, rash, increased sweating, and hives. Serious but less common reactions include serotonin syndrome (a constellation of symptoms that can resemble neuroleptic malignant syndrome), severe allergic reactions, seizures, serious skin reactions such as Stevens-Johnson syndrome or erythema multiforme, and liver problems ranging from abnormal liver function to liver failure or damage. If your family member develops a high fever, muscle stiffness, confusion, rapid heart rate, severe rash with blistering, yellowing of the skin or eyes, or any other sudden concerning change, seek medical attention promptly.
Common off-label uses observed in AU practice — none of these are TGA-approved indications for this substance. If the documented purpose is one of these, the prescription falls outside the TGA-approved set and may sit inside the chemical-restraint frame depending on jurisdiction and context.
These are practitioner observations, not TGA-approved indications. A use being off-label does not by itself imply a regulated restrictive practice; review the documented purpose against the observed function in context.
Tier 4 · Observation“The antidepressant and antiobsessional action of fluoxetine is presumed to be linked to its inhibition of CNS neuronal uptake of serotonin.”
“The relatively slow elimination of fluoxetine (elimination half-life of 1 to 3 days after acute administration and 4 to 6 days after chronic administration) and its active metabolite, norfluoxetine (elimination half-life of 4 to 16 days after acute and chronic administration), leads to significant accumulation of these active species in chronic use.”
A plain-language summary of the cited sources below. Informational only — not medical advice.
Fluoxetine is a selective serotonin reuptake inhibitor whose antidepressant and antiobsessional action is presumed to be linked to its inhibition of CNS neuronal uptake of serotonin. It carries TGA approval for major depression, obsessive compulsive disorder, and premenstrual dysphoric disorder as defined by DSM-IV criteria. Fluoxetine exhibits relatively slow elimination, with a half-life of 1 to 3 days after acute administration and 4 to 6 days after chronic administration; its active metabolite norfluoxetine has a half-life of 4 to 16 days after both acute and chronic dosing, leading to significant accumulation of these active species in chronic use.
Multiple cytochrome P450 isoenzymes, including CYP2D6, are responsible for the conversion of fluoxetine to norfluoxetine, though other nonsaturable oxidative pathways contribute considerably to norfluoxetine formation. Concomitant use with pimozide is contraindicated, as is combination with metoprolol used in cardiac failure. Fluoxetine should not be used in combination with a monoamine oxidase inhibitor or within a minimum of 14 days of discontinuing MAOI therapy. Common adverse effects include fatigue, diarrhoea, nausea, anxiety, dizziness, headache, insomnia, nervousness, somnolence, tremor, anorexia, dyspepsia, gastrointestinal disorder, mouth dryness, vomiting, pruritus, rash, sweating, and urticaria. Serious adverse effects include serotonin syndrome, anaphylactoid reaction, seizures, Stevens-Johnson syndrome, erythema multiforme, abnormal hepatic function, aggravation of hepatic damage, hepatic failure or necrosis, and idiosyncratic hepatitis.
Working under the parallel aged-care framework? Aged-care equivalent →
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.
“Multiple cytochrome P450 isoenzymes, including CYP2D6, are responsible for the conversion of fluoxetine to norfluoxetine; thus other nonsaturable oxidative pathways (i.e. non-2D6 pathways) contribute considerably to norfluoxetine formation”